Evidence map›Paper›PMID 26703964›Full record

Trial reportHaematologica2016

Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study.

Massimo Federico, Stefano Luminari, Cinzia Pellegrini, Francesco Merli, Emanuela Anna Pesce, Stephane Chauvie, Letizia Gandolfi, Isabella Capodanno, Massimiliano Salati, Lisa Argnani and 1 more

Abstract readClinical Trial, Phase IILetterMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. The GHSG Approach to Treating Hodgkin's Lymphoma.Current hematologic malignancy reports · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Massimo FedericoDipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica, Università di Modena e Reggio Emilia, Modena, Italy massimo.federico@unimore.it.
Stefano LuminariDipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica, Università di Modena e Reggio Emilia, Modena, Italy.
Cinzia PellegriniInstitute of Hematology "L. e A. Seràgnoli", University of Bologna, Italy.
Francesco MerliArcispedale "Santa Maria Nuova" Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Reggio Emilia, Italy.
Emanuela Anna PesceDipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica, Università di Modena e Reggio Emilia, Modena, Italy.
Stephane ChauvieSanta Croce e Carle Hospital, Cuneo, Italy.
Letizia GandolfiInstitute of Hematology "L. e A. Seràgnoli", University of Bologna, Italy.
Isabella CapodannoArcispedale "Santa Maria Nuova" Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Reggio Emilia, Italy.
Massimiliano SalatiDipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica, Università di Modena e Reggio Emilia, Modena, Italy.
Lisa ArgnaniInstitute of Hematology "L. e A. Seràgnoli", University of Bologna, Italy.
Pier Luigi ZinzaniInstitute of Hematology "L. e A. Seràgnoli", University of Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAntineoplastic AgentsBrentuximab VedotinDrug Administration ScheduleFemaleFeverGamma RaysHodgkin DiseaseHumansImmunoconjugatesMaleMiddle AgedNauseaNeoplasm StagingNeutropeniaAntineoplastic AgentsBrentuximab VedotinImmunoconjugatesABVDbrentuximab vedotinearlyHodgkin lymphomaintermediateradiotherapytoxicity

Identifiers

PMID26703964
PMCPMC5004404

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.